607 related articles for article (PubMed ID: 36688021)
1. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
Tang SY; Tan JS; Pang XZ; Lee GH
World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
[TBL] [Abstract][Full Text] [Related]
2. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
3. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
4. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
5. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
[TBL] [Abstract][Full Text] [Related]
7. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
8. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
Cheng YM; Wang CC; Kao JH
Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
[TBL] [Abstract][Full Text] [Related]
9. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
[TBL] [Abstract][Full Text] [Related]
13. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
Staufer K; Huber-Schönauer U; Strebinger G; Pimingstorfer P; Suesse S; Scherzer TM; Paulweber B; Ferenci P; Stimpfl T; Yegles M; Datz C; Trauner M
J Hepatol; 2022 Oct; 77(4):918-930. PubMed ID: 35605744
[TBL] [Abstract][Full Text] [Related]
14. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
15. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.
Xie ZQ; Li HX; Wang BK; Yang ZM; Zhang ZY; Tan WL; Li WX; Wang QB; Yang L; Zhuang HK; Tang CW; Shang CZ; Chen YJ
Eur J Intern Med; 2023 Apr; 110():62-70. PubMed ID: 36754655
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
17. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
18. MAFLD: Renovation of clinical practice and disease awareness of fatty liver.
Kawaguchi T; Tsutsumi T; Nakano D; Torimura T
Hepatol Res; 2022 May; 52(5):422-432. PubMed ID: 34472683
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis.
Virk GS; Vajje J; Virk NK; Mannam R; Rehman W; Ghobriel NG; Mian IU; Usama M
Cureus; 2023 Aug; 15(8):e44413. PubMed ID: 37791219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]